RG7388 is currently undergoing clinical trials alone or in combination with other drugs for acute myeloid leukemia (phase I/II: NCT02670044, NCT03850535; phase III: NCT02545283), myeloma (phase I/II: NCT02633059), lymphoma (phase I/II: NCT03135262), breast cancer (phase I/II: NCT03566485), a combination of acute leukemias and solid tumors (phase I/II: NCT04029688) and glioblastoma bearing an unmethylated MGMT promoter (phase I/II: NCT03158389). Here, MGMT is linked to glioblastoma.